Advanced Proteome Therapeutics Announces First Results of Pilot Project
mcleanap2021-09-09T13:12:25-04:00Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has received first results as part of its collaborative pilot project with a promising Boston based biotechnology company (“Biotech”), as announced on February 10, 2020. The pilot project is testing APTI’s site specific conjugation technology with Biotech’s proprietary antibody against a high-value target.